Dabur Lines Up A Slew Of Ayurvedic Concoction Launch Soon

Dabur India Ltd has plans to launch an entire range of ayurvedic products in the domestic market soon.

According to DB Anantha Narayana, director, Dabur Research Foundation, "Dabur is looking to launch approximately 10 to 20 new products by next year."

In fact, Dabur would be introducing a new range of ayurvedic medicinal products for women within the next two months.

The company also has plans to launch a balm and a new variant of chyavanprash by next year.

"Dabur is looking at attaining 25 per cent of its revenues from these new products," says Sunil Duggal, director, sales and marketing, Dabur India Ltd.

However, says Narayana, the thrust would be on positioning the drugs as prescription products rather than over-the-counter (OTC) drugs.

Dabur India would, for the first two years, keep the drugs prescription-oriented, as this would provide a safeguard from similar copies in the market that might emerge, he said.

The company is also focusing on exports of ayurvedic products into new markets this year. These include South Africa (subject to a decision by the South African government to allow import of ayurvedic drugs, which will be finalised in August this year), Russia and Malaysia.

Further, Dabur Research Foundation has reached an memorandum of understanding (MoU) with the Central Council of Research in Ayurveda and Siddha (CCRAS), a council under the Ministry of Health and Family Welfare, for the development of a new drug.

The agreement is aimed at undertaking further upstream research and development working in respect of ginger-based formulations developed by CCRAS for the treatment of rheumatoid arthritis.

The drugs in question are Sunthi-Guggulu and Sunthi-Guduchi. These drugs have been found to be effective in the treatment of the disease and its commercial exploitation thereafter.

Dabur Research Foundation will undertake upstream research work on these two products which would include development of a more consumer-friendly dosage form, scaling up the production process for the same, unit dose regulation and further clinical research.